Total Payments
$1.2M
2024 Payments
$152,898
Companies
90
Transactions
3,221
Medicare Patients
3,009
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$959,716 (77.3%)
Consulting$169,237 (13.6%)
Food & Beverage$56,919 (4.6%)
Travel$55,761 (4.5%)
Education$332.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $952,576 | 382 | 76.7% |
| Consulting Fee | $169,237 | 79 | 13.6% |
| Food and Beverage | $56,919 | 2,287 | 4.6% |
| Travel and Lodging | $55,761 | 458 | 4.5% |
| Honoraria | $7,140 | 6 | 0.6% |
| Education | $332.46 | 9 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $451,191 | 556 | $0 (2022) |
| ABBVIE INC. | $415,367 | 609 | $0 (2024) |
| Amgen Inc. | $140,522 | 275 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $72,725 | 128 | $0 (2021) |
| IMPEL PHARMACEUTICALS INC. | $32,442 | 41 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $24,845 | 179 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $20,088 | 63 | $0 (2021) |
| PFIZER INC. | $20,073 | 66 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $16,274 | 49 | $0 (2022) |
| Lundbeck LLC | $11,829 | 83 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152,898 | 307 | ABBVIE INC. ($143,922) |
| 2023 | $164,931 | 361 | AbbVie Inc. ($135,177) |
| 2022 | $169,561 | 377 | ABBVIE INC. ($90,488) |
| 2021 | $271,170 | 494 | Allergan, Inc. ($140,688) |
| 2020 | $184,256 | 406 | Allergan, Inc. ($155,285) |
| 2019 | $130,366 | 479 | Amgen Inc. ($61,448) |
| 2018 | $95,867 | 394 | Amgen Inc. ($37,712) |
| 2017 | $72,916 | 403 | Allergan Inc. ($42,068) |
All Payment Transactions
3,221 individual payment records from CMS Open Payments — Page 129 of 129
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/19/2017 | Cyberonics, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: VNS Therapy (Product Class) | ||||||
| 01/19/2017 | Pernix Therapeutics Holdings, Inc. | TREXIMET (Drug) | Food and Beverage | In-kind items and services | $8.27 | General |
| Category: NEUROLOGY | ||||||
| 01/18/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: Migraine | ||||||
| 01/18/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $1.99 | General |
| Category: Migraine | ||||||
| 01/18/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: Migraine | ||||||
| 01/16/2017 | Vertical Pharmaceuticals, LLC | LORZONE (Drug), CONZIP | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: MUSCLE RELAXANT | ||||||
| 01/16/2017 | Teva Pharmaceuticals USA, Inc. | COPAXONE (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Central Nervous System | ||||||
| 01/16/2017 | Teva Pharmaceuticals USA, Inc. | COPAXONE (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Central Nervous System | ||||||
| 01/12/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Migraine | ||||||
| 01/12/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $8.32 | General |
| Category: NEUROSCIENCE | ||||||
| 01/12/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $1.58 | General |
| Category: Migraine | ||||||
| 01/11/2017 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Immunology and Neurology | ||||||
| 01/10/2017 | Arbor Pharmaceuticals, Inc. | Horizant (Drug) | Food and Beverage | Cash or cash equivalent | $12.06 | General |
| Category: Sleep | ||||||
| 01/10/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $9.53 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 01/10/2017 | Pernix Therapeutics Holdings, Inc. | TREXIMET (Drug) | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: NEUROLOGY | ||||||
| 01/09/2017 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $19.83 | General |
| Category: NEUROLOGY | ||||||
| 01/09/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $7.61 | General |
| Category: NEUROSCIENCE | ||||||
| 01/06/2017 | Promius Pharma LLC | Zembrace (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Neurology | ||||||
| 01/03/2017 | Allergan Inc. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 01/03/2017 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | Cash or cash equivalent | $28.68 | General |
| Category: Musculoskeletal | ||||||
| 01/03/2017 | Pernix Therapeutics Holdings, Inc. | TREXIMET (Drug) | Food and Beverage | In-kind items and services | $9.83 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 738 | 61,492 | $1.0M | $381,559 |
| 2022 | 19 | 871 | 60,794 | $1.1M | $381,474 |
| 2021 | 18 | 709 | 61,895 | $1.1M | $388,552 |
| 2020 | 18 | 691 | 54,975 | $996,897 | $344,129 |
Total Patients
3,009
Total Services
239,156
Medicare Billing
$1.5M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 85 | 59,800 | $598,000 | $290,112 | 48.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 56 | 187 | $149,600 | $20,549 | 13.7% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2023 | 92 | 713 | $28,520 | $17,994 | 63.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 58 | 194 | $43,650 | $7,744 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 80 | $44,000 | $6,593 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 98 | $29,400 | $6,431 | 21.9% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2023 | 59 | 63 | $27,056 | $5,851 | 21.6% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2023 | 80 | 86 | $21,328 | $5,487 | 25.7% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 12 | 36 | $28,800 | $5,078 | 17.6% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 24 | 72 | $5,400 | $3,985 | 73.8% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2023 | 91 | 98 | $26,484 | $3,481 | 13.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $11,250 | $2,470 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 19 | $12,825 | $2,220 | 17.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $4,980 | $2,058 | 41.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 16 | $2,688 | $1,506 | 56.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 81 | 58,900 | $589,000 | $281,050 | 47.7% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2022 | 119 | 774 | $30,960 | $20,213 | 65.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 50 | 170 | $136,000 | $18,545 | 13.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 61 | 226 | $50,850 | $9,117 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 90 | $49,500 | $7,768 | 15.7% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2022 | 74 | 75 | $52,200 | $7,192 | 13.8% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2022 | 82 | 86 | $21,328 | $5,670 | 26.6% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 27 | 83 | $6,225 | $4,680 | 75.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2022 | 12 | 37 | $11,100 | $4,598 | 41.4% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2022 | 117 | 124 | $73,656 | $4,555 | 6.2% |
About Dr. Ravi Shah, MD
Dr. Ravi Shah, MD is a Neurology healthcare provider based in Parker, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013999895.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ravi Shah, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $152,898 received in 2024. These payments were reported across 3,221 transactions from 90 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($952,576).
As a Medicare-enrolled provider, Shah has provided services to 3,009 Medicare beneficiaries, totaling 239,156 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Parker, CO
- Active Since 11/16/2005
- Last Updated 05/06/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013999895
Products in Payments
- BOTOX (Biological) $464,302
- UBRELVY (Drug) $222,023
- Aimovig (Biological) $120,067
- NURTEC ODT (Drug) $108,631
- QULIPTA (Drug) $75,215
- BOTOX (Drug) $55,537
- Trudhesa (Drug) $32,442
- BOTOX CHRONIC MIGRAINE (Drug) $21,314
- ONZETRA Xsail (Drug) $18,167
- AJOVY (Drug) $14,218
- VYEPTI (Biological) $11,328
- AJOVY (Biological) $9,686
- Cambia (Drug) $5,951
- BOTOX - MIGRAINE (Drug) $5,762
- TREXIMET (Drug) $5,050
- TROKENDI XR (Drug) $4,129
- Zembrace (Drug) $2,028
- ZEMBRACE SYMTOUCH (Drug) $1,635
- NUEDEXTA (Drug) $1,166
- ONZETRA (Drug) $770.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.